RDHL

Redhill Boipharma Share Price - RDHL

8.84
-0.01 (-0.11%)
Upgrade to Real-Time
Afterhours (Closed)
8.84
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Redhill Boipharma Ltd RDHL NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-0.01 -0.11% 8.84 16:45:16
Open Price Low Price High Price Close Price Previous Close
8.96 8.8015 9.10 8.84 8.85
Bid Price Ask Price Spread News
8.50 9.30 0.80 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
1,552 194,854  8.93  1,740,754 274,039
Last Trade Time Type Quantity Stock Price Currency
17:01:06 5  8.84 USD

Redhill Boipharma Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 333.22M 37.69M 37.69M  6.29M  - -0.50 -5.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News Redhill Boipharma

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

RDHL Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.


Your Recent History
NASDAQ
RDHL
Redhill Bo..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.